Dihydroartemisinin Regulates Self-Renewal of Human Melanoma-Initiating Cells by Targeting PKM2/LDHARelated Glycolysis
Objectives: Melanoma-initiating cells (MICs), a group of cells with stem cell-like self-renewal ability, play a vital role in melanoma progression. They are energized by PKM2/LDHA-related glycolysis. Dihydroartemisin (DHA), a derivative of the antimalarial drug artemisinin, reportedly has a potential role in glycolysis regulation. The aim of this study was to detect the regulation of self-renewal of MICs by DHA through PKM2/LDHA-related glycolysis.
Methods: The cell viability of melanoma cells following DHA treatment in vitro was measured by MTS. Cell cycle were detected by Flow cytometry. And DHA treatment in vivo was measured by Nude mouse xenograft assay. MICs selfrenewal was detected by stem cell related spheres culture and assays.
Results: DHA inhibits the proliferation of melanoma cells and blocks the cell cycle process. Importantly, it suppresses the selfrenewal of MICs. Furthermore, DHA reduces ATP production and downregulate PKM2 and LDHA activities without regulating the expression of the PKM2 and LDHA proteins in melanoma cells. Moreover, DHA covalently binds to the protein skeleton of PKM2 and LDHA through its sesquiterpene lactone structure and downregulates glucose metabolism in melanoma cells.
Conclusion: These findings revealed that DHA regulates self-renewal of human MICs by targeting PKM2/LDHA-related glycolysis.
1. Tasdogan A, Faubert B, Ramesh V, Ubellacker JM, Shen B, Solmonson A, et al. Metabolic heterogeneity confers differences in melanoma metastatic potential. Nature 2020;577:115–20.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70:7–30.
3. Du Y, Shao H, Moller M, Prokupets R, Tse YT, Liu ZJ. Intracellular Notch1 signaling in cancer-associated fibroblasts dictates the plasticity and stemness of melanoma stem/initiating cells. Stem Cells 2019;37:865–75.
4. Lee J, Abdeen AA, Hedhli J, Wycislo KL, Dobrucka IT, Fan TM, et al. Melanoma topology reveals a stem-like phenotype that promotes angiogenesis. Sci Adv 2017;3:e1701350.
5. Santini R, Pietrobono S, Pandolfi S, Montagnani V, D'Amico M, Penachioni JY, et al. SOX2 regulates self-renewal and tumorigenicity of human melanoma-initiating cells. Oncogene 2014;33:4697–708.
6. Paschen A, Baingo J, Schadendorf D. Expression of stress ligands of the immunoreceptor NKG2D in melanoma: Regulation and clinical significance. Eur J Cell Biol 2014;93:49–54.
7. Suzuki N, Tanaka M, Shirafuji Y, Otsuka M, Yamasaki O, Asagoe K, et al. Assessment of melanoma-initiating cell markers and conventional parameters in sentinel lymph nodes of malignant melanoma. Acta Med Okayama 2015;69:17–27.
8. Le Coz V, Zhu C, Devocelle A, Vazquez A, Boucheix C, Azzi S, et al. IGF-1 contributes to the expansion of melanoma-initiating cells through an epithelial-mesenchymal transition process. Oncotarget 2016;7:82511–27.
9. Mukherjee N, Lu Y, Almeida A, Lambert K, Shiau CW, Su JC, et al. Use of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells. Oncotarget 2017;8:46801–17.
10. Mukherjee N, Strosnider A, Vagher B, Lambert KA, Slaven S, Robinson WA, et al. BH3 mimetics induce apoptosis independent of DRP-1 in melanoma. Cell Death Dis 2018;9:907.
11. Pietrobono S, Morandi A, Gagliardi S, Gerlini G, Borgognoni L, Chiarugi P, et al. Down-regulation of SOX2 underlies the inhibitory effects of the triphenylmethane gentian violet on melanoma cell self-renewal and survival. J Invest Dermatol 2016;136:2059–69.
12. Koch A, Ebert EV, Seitz T, Dietrich P, Berneburg M, Bosserhoff A, et al. Characterization of glycolysis-related gene expression in malignant melanoma. Pathol Res Pract 2020;216:152752.
13. Ruocco MR, Avagliano A, Granato G, Vigliar E, Masone S, Montagnani S, et al. Metabolic flexibility in melanoma: A potential therapeutic target. Semin Cancer Biol 2019;59:187–207.
14. Zhou Y, Huang Z, Su J, Li J, Zhao S, Wu L, et al. Benserazide is a novel inhibitor targeting PKM2 for melanoma treatment. Int J Cancer 2020;147:139–51.
15. Pathria G, Scott DA, Feng Y, Sang Lee J, Fujita Y, Zhang G, et al. Targeting the Warburg effect via LDHA inhibition engages ATF4 signaling for cancer cell survival. EMBO J 2018;37:e99735.
16. Zhang H, Feng C, Zhang M, Zeng A, Si L, Yu N, et al. miR-625- 5p/PKM2 negatively regulates melanoma glycolysis state. J Cell Biochem 2019;120:2964–72.
17. Zhao X, Zhu Y, Hu J, Jiang L, Li L, Jia S, et al. Shikonin inhibits tumor growth in mice by suppressing pyruvate kinase M2- mediated aerobic glycolysis. Sci Rep 2018;8:14517.
18. Jin C, Dong D, Yang Z, Xia R, Tao S, Piao M. CircMYC Regulates glycolysis and cell proliferation in melanoma. Cell Biochem Biophys 2020;78:77–88.
19. Bian Z, Zhang J, Li M, Feng Y, Wang X, Zhang J, et al. LncRNAFEZF1-AS1 promotes tumor proliferation and metastasis in colorectal cancer by regulating PKM2 signaling. Clin Cancer Res 2018;24:4808–19.
20. Zheng B, Geng L, Zeng L, Liu F, Huang Q. AKT2 contributes to increase ovarian cancer cell migration and invasion through the AKT2-PKM2-STAT3/NF-κB axis. Cell Signal 2018;45:122–31.
21. Jurisic V, Radenkovic S, Konjevic G. The actual role of LDH as tumor marker, biochemical and clinical aspects. Adv Exp Med Biol 2015;867:115–24.
22. Sundstrøm T, Espedal H, Harter PN, Fasmer KE, Skaftnesmo KO, Horn S, et al. Melanoma brain metastasis is independent of lactate dehydrogenase: A expression. Neuro Oncol 2015;17:1374–85.
23. Daneshmandi S, Wegiel B, Seth P. Blockade of Lactate Dehydrogenase-A (LDH-A) improves efficacy of Anti-Programmed Cell Death-1 (PD-1) therapy in melanoma. Cancers (Basel) 2019;11:450.
24. Kumar MS, Yadav TT, Khair RR, Peters GJ, Yergeri MC. Combination therapies of artemisinin and its derivatives as a viable approach for future cancer treatment. Curr Pharm Des 2019;25:3323–38.
25. Yao Y, Guo Q, Cao Y, Qiu Y, Tan R, Yu Z, et al. Artemisinin derivatives inactivate cancer-associated fibroblasts through suppressing TGF-β signaling in breast cancer. J Exp Clin Cancer Res 2018;37:282.
26. Sun X, Yan P, Zou C, Wong YK, Shu Y, Lee YM, et al. Targeting autophagy enhances the anticancer effect of artemisinin and its derivatives. Med Res Rev 2019;39:2172–93.
27. Yang DX, Qiu J, Zhou HH, Yu Y, Zhou DL, Xu Y, et al. Dihydroartemisinin alleviates oxidative stress in bleomycin-induced pulmonary fibrosis. Life Sci 2018;205:176–83.
28. Yan X, Li P, Zhan Y, Qi M, Liu J, An Z, et al. Dihydroartemisinin suppresses STAT3 signaling and Mcl-1 and Survivin expression to potentiate ABT-263-induced apoptosis in Non-small Cell Lung Cancer cells harboring EGFR or RAS mutation. Biochem Pharmacol 2018;150:72–85.
29. Wang Z, Duan X, Lv Y, Zhao Y. Low density lipoprotein receptor (LDLR)-targeted lipid nanoparticles for the delivery of sorafenib and Dihydroartemisinin in liver cancers. Life Sci 2019;239:117013.
30. Yao Z, Bhandari A, Wang Y, Pan Y, Yang F, Chen R, et al. Dihydroartemisinin potentiates antitumor activity of 5-fluorouracil against a resistant colorectal cancer cell line. Biochem Biophys Res Commun 2018;501:636–42.
31. Li YH, Li XF, Liu JT, Wang H, Fan LL, Li J, et al. PKM2, a potential target for regulating cancer. Gene 2018;668:48–53.
32. Cholia RP, Dhiman M, Kumar R, Mantha AK. Oxidative stress stimulates invasive potential in rat C6 and human U-87 MG glioblastoma cells via activation and cross-talk between PKM2, ENPP2 and APE1 enzymes. Metab Brain Dis 2018;33:1307–26.
33. Yang D, Peng M, Hou Y, Qin Y, Wan X, Zhu P, et al. Oxidized ATM promotes breast cancer stem cell enrichment through energy metabolism reprogram-mediated acetyl-CoA accumulation. Cell Death Dis 2020;11:508.
34. Hermans D, Gautam S, García-Cañaveras JC, Gromer D, Mitra S, Spolski R, et al. Lactate dehydrogenase inhibition synergizes with IL-21 to promote CD8+ T cell stemness and antitumor immunity. Proc Natl Acad Sci U S A 2020;117:6047–55.